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Aneurysm Surgery: The Quest of the GrailWhile the results of prophylactic abdominal aortic aneu-
rysm (AAA) repair have steadily improved over recent de-
cades, the incidence of acute kidney injury (AKI) remains
high.1 AKI can be associated with increased post-operative
mortality, need for renal replacement therapy (RRT),
longer hospital stay, and higher healthcare costs with even a
residual risk of death at least one year after surgery.
The incidence of AKI after AAA repair can vary according
to the type and complexity of surgical treatment, the pa-
tient’s risk factors, and the definition of AKI used.2 Since
2012, the universally accepted criteria recommended for
AKI identification and severity classification are those
defined by the Kidney Disease Improving Global Outcomes
guidelines, including both serum creatinine (sCr) level and
urine output (UO).3 Three stages have been defined for AKI
severity evaluation, the third one usually linked to RRT.
Open AAA repair (OAR) continues to be used in patients
unsuitable for endovascular aneurysm repair (EVAR), as well
as in countries where healthcare resources are limited.
While infrarenal aortic cross clamping is preferred, supra-
renal or supracoeliac clamping may be necessary if the
aneurysm extends above the renal arteries, increasing rates
of AKI and peri-operative morbidity. Similarly, in the case of
a hostile neck, the suprarenal portion of the aorta can be
used for sealing fenestrated (fEVAR), branched (bEVAR), or
chimney grafts.2 The complexity of surgery is associated
with a potential risk of longer procedure time and the use
of more contrast, well known factors for AKI.1
Careful management of patients at high AKI risk includes
optimising the volume status and haemodynamics (main-
tenance of adequate blood pressure) and avoiding neph-
rotoxic agents and hydroxy starch colloid solutions. This can
reduce (but not suppress) the development and morbidity
of peri-operative AKI.
In this issue of EJVES, Saratzis et al.4 report an AKI inci-
dence of 28% after AAA repair in a multicentre UK pro-
spective cohort including 300 patients (91% males, mean
age 71 years), some submitted to complex surgery with f/b
EVAR and OAR. While 24% developed stage 1 AKI, renal
decline (estimated by a drop of estimated glomerular
filtration rate [eGFR] > 20%) occurred in >25% (37% after
fEVAR) at 30 days and reached 30% at one year, despite
following the aforementioned recommendations.1078-5884/ 2020 European Society for Vascular Surgery. Published by
Elsevier B.V. All rights reserved.
https://doi.org/10.1016/j.ejvs.2020.01.037CAN THE INCIDENCE OF ACUTE KIDNEY INJURY AFTER AAA
REPAIR BE DECREASED?
Therapeutic choices in AKI are still confined to supportive
care and preventive strategies. For the prevention of AKI, it
is first important to identify the patient related factors, such
as older age and pre-existing CKD, procedure related fac-
tors, such as the complexity of surgery, and procedure
related complications, such as sepsis.
sCr must be measured immediately prior to surgery in all
patients, and by using sCr based eGFR equations kidney
function can be determined in patientswith a steady state pre-
operatively so as to ascertain AKI post-operatively. The pa-
tients must then be re-assessed within the first 12 post-
operative hours incorporating intra-operative and post-
operative variables, such as UO. A possible error here could
be an overestimation of baseline kidney function, erroneously
reassuring the physician owing to inaccuracy of sCr as amarker
of eGFR in some populations (the very elderly, those with low
muscle mass, those overhydrated by haemodilution). In pa-
tients at high risk of AKI, some authors recommendmeasuring
tubular damage biomarkers such as urinary TIMP2IGFBP7 (a
combination of tissue inhibitor of metalloproteinase-2 and
insulin like growth factor binding protein-7, two cell cycle ar-
rest biomarkers). It is speculated that such early biomarkers
potentially may provide earlier diagnosis and also prognosis
information independent of the conventional sCr and UO
markers of AKI.5 However, currently, the benefit and cost
effectiveness of this strategy still need validation.
Prevention also needs to understand the mechanisms of
AKI that are multifactorial
According to the recent consensus for cardiac and vascular
surgery associated AKI prevention,3 in the pre-operative
stage, withholding renin angiotensin blockers and limiting
large use of intravenous contrast agents can reduce the
incidence of AKI. In the peri-operative period, haemody-
namic optimisation to maintain renal perfusion is crucial.
The quality of EVAR techniques should also be improved,
with less irradiation, contrast use, and aortic manipulation
with its high risk of athero-emboli and lengthening of pro-
cedure time. Aortic clamping above both renal arteries in-
creases the incidence of AKI. Cold renal perfusion has been
suggested for pararenal AAA surgery. Embolic protection
devices may help to prevent procedure related athero-
emboli during endovascular renal intervention. In the
post-operative period, maintenance of haemodynamics
Editorial 867(mean arterial pressure > 65 mmHg), avoidance of neph-
rotoxic agents, and prevention of sepsis remain crucial.
Some hopes for better prevention of AKI were invested in
remote ischaemic preconditioning, but the results have been
conflicting in vascular surgery.6,7 Two other recent methods
seemed to be more promising and are the target of active
research. The first hope is the use of mesenchymal stem cell
(MSC) therapy administered just before high risk surgery with
ischaemia reperfusion.8 TheseMSCs have immunomodulatory
and tissue repairing properties and may represent a novel
approach in AKI for renal ischaemia reperfusion. However, in
cardiac surgery, the results of the first clinical trial were
neutral.9 Additional work in vascular surgery is needed.
The second hope comes from the nicotinamide adenine
dinucleotide (NADþ) store restoration, which can be asso-
ciated with less AKI in ischaemic conditions.10 Indeed, NADþ
is a universal electron acceptor from glycolysis and the
Krebs cycle, and the substrate for non-redox enzymes that
consume NADþ at the mitochondria. In critically ill patients,
there is a huge metabolic stress, which can lead to AKI. In
humans, the urine of those who will develop AKI has a
higher concentration of quinolinate and an elevated urinary
quinolinate/tryptophan ratio due to a decrease in the ac-
tivity of the enzyme quinolinate phosphoribosyltransferase,
which defends NADþ and mediates resistance to AKI. During
a pilot study performed in 55 people, with once daily
administration by mouth or orogastric tube, the day prior,
the day of, and the day after on pump cardiac surgery, of a
high dose (1e3 g/day) of nicotinamide, a dose related in-
crease in circulating NADþ metabolites was observed, with
good tolerance of the drug and less AKI development. This is
promising but needs to be confirmed in a larger study.11
The take home message from the work published by
Saratzis et al.4 is that, despite careful measures, the inci-
dence of AKI after AAA repair remains high. This emphasises
the need for continuous research to improve the diagnosis,
prevention, and treatment of AKI after aortic surgery. In the
meantime, we need to continue to follow the advice of the
recently published AAA clinical practice guidelines of the
European Society for Vascular Surgery: “In patients under-
going abdominal aortic aneurysm repair, assessment of pre-
operative kidney function by measuring serum creatinine
and estimating GFR is recommended, and those with severe
renal impairment (estimated glomerular filtration
rate < 30 mL/min/1.73 m2) should be quickly referred to a
renal physician”.12
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